Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. (SRPT) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Sarepta Therapeutics, Inc. (SRPT), featuring income statements, balance sheets, and cash flow data.
Sarepta Therapeutics, Inc. (SRPT) Income Statement & Financial Overview
View the income breakdown for Sarepta Therapeutics, Inc. SRPT across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $744.86M | $658.41M | $467.17M | $362.93M |
| Cost of Revenue | $137.56M | $132.30M | $91.69M | $53.26M |
| Gross Profit | $607.29M | $515.65M | $375.48M | $309.67M |
| Gross Profit Ratio | $0.82 | $0.78 | $0.80 | $0.85 |
| R&D Expenses | $773.45M | $199.95M | $224.48M | $173.71M |
| SG&A Expenses | $133.63M | $163.87M | $128.20M | $136.66M |
| Operating Expenses | $907.68M | $364.43M | $353.29M | $310.37M |
| Total Costs & Expenses | $1.05B | $496.73M | $444.98M | $363.63M |
| Interest Income | $12.43M | $14.70M | $18.33M | $18.84M |
| Interest Expense | $4.50M | $4.47M | $4.92M | $4.83M |
| Depreciation & Amortization | $9.98M | $14.33M | $9.81M | $12.73M |
| EBITDA | -$369.04M | $190.55M | $48.73M | $12.03M |
| EBITDA Ratio | -$0.50 | $0.29 | $0.10 | $0.03 |
| Operating Income | -$300.39M | $161.68M | $22.20M | -$701000.00 |
| Operating Income Ratio | -$0.40 | $0.25 | $0.05 | -$0.002 |
| Other Income/Expenses (Net) | -$83.13M | $10.06M | $11.81M | $14.28M |
| Income Before Tax | -$383.52M | $171.74M | $34.006M | $13.58M |
| Income Before Tax Ratio | -$0.51 | $0.26 | $0.07 | $0.04 |
| Income Tax Expense | $63.99M | $12.69M | $395000.00 | $7.12M |
| Net Income | -$447.51M | $159.05M | $33.61M | $6.46M |
| Net Income Ratio | -$0.60 | $0.24 | $0.07 | $0.02 |
| EPS | -$4.60 | $1.65 | $0.35 | $0.07 |
| Diluted EPS | -$4.60 | $1.50 | $0.33 | $0.07 |
| Weighted Avg Shares Outstanding | $97.36M | $96.28M | $95.39M | $94.62M |
| Weighted Avg Shares Outstanding (Diluted) | $97.36M | $108.47M | $100.45M | $94.62M |
The company's financials show resilient growth, with revenue advancing from $362.93M in Q2 2024 to $744.86M in Q1 2025. Gross profit remained healthy with margins at 82% in Q1 2025 compared to 85% in Q2 2024. Operating income hit -$300.39M last quarter, sustaining a consistent -40% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$369.04M. Net income dropped to -$447.51M, while earnings per share reached -$4.60. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan